Skip to main content

Table 3 Overview of prevalence of specific mutations specified for each molecular diagnosis

From: Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics

Molecular diagnosis TP53 FUBP1 CIC ATRX PTEN NOTCH1 PIK3CA
n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Astrocytoma 114 (97.4) 1 (0.9) 3 (2.6) 85 (72.6) 6 (5.1) 9 (7.7) 1 (0.9)
Oligodendroglioma 3 (5.6) 15 (27.8) 26 (48.1) 2 (3.7) 5 (9.3) 7 (13.0) 3 (5.6)
Glioblastoma 45 (25.1) 0 (0) 7 (3.9) 6 (3.4) 81 (45.3) 8 (4.5) 2 (1.1)
H3F3A K27 M-mutated tumor 7 (77.8) 1 (11.1) 0 (0) 1 (11.1) 1 (11.1) 1 (11.1) 1 (10.0)
H3F3A G34 M-mutated tumor 3 (100) 0 (0) 1 (33.3) 3 (100) 0 (0) 0 (0) 0 (0)
BRAF-mutated tumor 1 (6.7) 1 (6.7) 1 (6.7) 0 (0) 0 (0) 1 (6.7) 1 (6.7)
Unclassifying mutations 10 (27.0) 1 (2.7) 1 (2.7) 7 (18.9) 8 (21.6) 3 (8.1) 2 (5.4)